Demographics add urgency for action on dementia long-term care.

Esther M. Friedman

2014-07-28

Modern Healthcare

Abstract:

What problem does this paper attempt to address?

Delayed and localized pemphigus vulgaris after breast cancer radiotherapy

Hiu Kwan Carolyn Tang,Doreen Yin Hui Lee,Ian Thompson,John R. Ingram,Natalie Stone,Girish K. Patel

DOI: https://doi.org/10.1111/tbj.12910

2017-09-11

The Breast Journal

Abstract:Breast cancer treatment involving ionizing radiation causes characteristic radiation dermatitis in the majority of patients. The DNA damaging effects of radiation can rarely predispose to primary inflammatory dermatoses, such as pemphigus vulgaris. In such cases, the disease presents with all the hallmarks of the primary dermatosis, but the eruption is limited to the field of irradiation and is often amenable to treatment. In contrast, occurrence of generalized pemphigus vulgaris in this setting may mean cancer recurrence. The mechanism by which radiotherapy induces localized disease remains unknown, but there is likely a loss of self-tolerance which maybe coupled to antigen exposure.
Post-Irradiation Morphea of the Breast in a Patient with Subacute Cutaneous Lupus Erythematosus: Case Report and a Literature Review

Carole Anouk Zahn,Laurence Feldmeyer,Roland Blum,Carlo Mainetti

DOI: https://doi.org/10.1159/000524514

2022-05-31

Case Reports in Dermatology

Abstract:The appearance of morphea after radiotherapy, especially in the context of breast cancer, is a rare but known phenomenon. The incidence of post-irradiation morphea (PIM) of the breast is approximately one in every 500 patients, a higher rate than morphea of any other etiology, which is three per 100 , 000 per year. PIM usually appears less than 1 year after irradiation (range 1 month to 32 years). The histological pattern of PIM is different from the one in post-irradiation fibrosis, which is a common side effect of radiotherapy and usually appears during the first 3 months after irradiation. Several theories have been proposed to explain the pathogenesis of PIM, probably caused by a disturbance of the cytokine pattern. The development of PIM in patients with autoimmune diseases has been described in the literature. To our knowledge, we report the first case of PIM in a patient with subacute cutaneous lupus erythematosus. We should therefore pay attention when looking at patients with PIM to search for an underlying autoimmune disease. Case Rep Dermatol 2022;14:144–150
Deformities of the metacarpus and metatarsus in fallow deer (Dama dama L.).

D. Chapman,N. Chapman,L. Jeffcott

DOI: https://doi.org/10.1016/0021-9975(84)90010-0

IF: 1.083

Journal of Comparative Pathology

Abstract:
Case report of a delayed diagnosis of radiation induced ulcer in a patient following angioplasty

Gabrielle Harvey,Andréanne Waddell,Marc-Antoine Despatis

DOI: https://doi.org/10.1177/2050313X241289593

2024-10-09

Abstract:Diagnosis of fluoroscopy-induced radiodermatitis remains challenging for dermatologists. We present a case report where a patient had predictable risks of developing chronic radiodermatitis, yet the diagnostic was delayed for over a year and a half. In the current absence of appropriate follow-ups in some institutions, dermatologists should keep high suspicion for chronic fluoroscopy-induced radiodermatitis when encountering lesions characteristic of radiation dermatitis without a history of radiotherapy, prompting the necessity to inquire about antecedents of fluoroscopy-guided interventions.
Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report

Tulika Chatterjee,Thomas F Rashid,Salman B Syed,Moni Roy

DOI: https://doi.org/10.7759/cureus.21770

2022-01-31

Cureus

Abstract:Pembrolizumab is an immune checkpoint inhibitor being increasingly used as immunotherapy for a multitude of cancers. With the increasing use of these agents, various immune-related adverse events are being recognized. Lichenoid reaction, pruritus, and eczema are well-established cutaneous side effects of pembrolizumab, but bullous pemphigoid (BP) is a rare side effect of the drug. It is difficult to establish this diagnosis because it needs a detailed history of the timeline of the evolution of symptoms and careful ruling out of other etiologies, especially other drugs. Here, we present the case of a 66-year-old male who developed BP after receiving pembrolizumab therapy for non-small-cell lung cancer. Discontinuation of pembrolizumab and the use of topical and systemic steroids led to the complete resolution of symptoms. Physicians should be aware of this potential complication and keep it on their differential diagnosis when treating patients on immune checkpoint inhibitors.
[Trichinelliasis, a parasitosis of renewed current interest].

M. Luca,I. Zaharia,O. Stanciu

Abstract:
Radiation-induced cutaneous vasculopathy of the breast: a rare case report

Hilde Van Parijs,Yves Sinove,Marilyn Carprieaux,Mark De Ridder

DOI: https://doi.org/10.1186/s12957-024-03346-0

2024-02-21

World Journal of Surgical Oncology

Abstract:Radiation therapy is often indicated as part of the treatment for breast cancer and is therefore used frequently worldwide. Vasculopathy is a general term used to describe any condition that affects blood vessels. We present a case report of a patient who presented with vasculopathy as a rare late side effect of radiation therapy to the breast.

oncology,surgery
Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature

Aikaterini Tsiogka,Johann W Bauer,Aikaterini Patsatsi

DOI: https://doi.org/10.2340/00015555-3740

2021-01-20

Abstract:Bullous pemphigoid constitutes a rare dermatological immune-related adverse event of programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors. Herein, we review all published cases of anti-PD-1/PD-L1 related bullous pemphigoid and discuss current knowledge on this condition. Clinical and diagnostic findings were found to resemble those of classic bullous pemphigoid. A delayed onset of bullous pemphigoid after commencement of immunotherapy as well as a frequent precendence of a refractory pruritic eruption prior to blister development was oberved, both posing diagnostic challenges. In addition to topical and systemic treatment, most patients required either discontinuation or permanent interruption of immunotherapy. Assessment of tumour outcome did not reveal improved survival in patients developing bullous pemphigoid during immunotherapy, as suggested for other types of skin toxicity, including vitiligo. Better understanding of the pathogenetic mechanism and prognostic implications of this increasingly-reported adverse event is essential in order to establish optimal diagnostic and therapeutic management of these patients.
Atypical Presentation of Severe Bullous Pemphigoid: A Case Report

Tinotenda Sekeramayi,Sara Ruter

Abstract:Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disorder. Typically, patients will present with tense bullae and intense generalized pruritus with a skin biopsy demonstrating subepidermal split with eosinophils and a direct immunofluorescence highlighting autoantibodies against the basement membrane zone. Prognosis varies, and treatment involves an assessment of the severity of disease to determine whether to initiate topical or systemic immunosuppressive agents. We present an atypical presentation of BP that presented as a 3-to-4-week duration of pruritic small vesicular lesions in the upper chest, scabbed circular lesions along the upper extremity and pinnas of bilateral ear. Initially thought to be herpes zoster infection initially treated with valacyclovir for a week following a prior concern of a concomitant superficial skin infection with cephalexin and prednisone. With no clinical improvement, tissue biopsy was performed that confirmed bullous pemphigoid and treatment with steroid taper, doxycycline, and triamcinolone acetonide 0.1% cream was started. The aim of this case report is to present an atypical presentation of BP and to highlight maintaining a high index of suspicion of BP in patients presenting with disseminated significantly pruritic lesions.
Viral respiratory disease in the intensive care unit.

R. Belshe

Abstract:
Ulcerating skin lesions from blastic plasmacytoid dendritic cell neoplasm responding to low-dose radiotherapy—a case report and literature review

Elgin Hoffmann,Simon Böke,Chiara De-Colle,Claudia Lengerke,Karim-Maximilian Niyazi,Cihan Gani

DOI: https://doi.org/10.1007/s00066-024-02200-2

2024-01-30

Strahlentherapie und Onkologie

Abstract:Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that can manifest with skin nodules and erythematous plaques. In most cases BPDCN progresses rapidly, causing multiple skin lesions and also affecting internal organs and bone marrow, warranting initiation of systemic therapies or hematopoietic stem cell transplantation (HCT). Although not curative, radiotherapy for isolated lesions might be indicated in case of (imminent) ulceration and large or symptomatic lesions. To this end, doses of 27.0–51.0 Gy have been reported. Here, we present the case of an 80-year-old male with BPDCN with multiple large, nodular, and ulcerating lesions of the thorax, abdomen, and face. Low-dose radiotherapy of 2 × 4.0 Gy was administered to several lesions, which resolved completely within 1 week with only light residual hyperpigmentation of the skin in affected areas and reliably prevented further ulceration. Radiotoxicity was not reported. Therefore, low-dose radiotherapy can be an effective and low-key treatment in selected cases of BPDCN, especially in a palliative setting, with a favorable toxicity profile.

oncology,radiology, nuclear medicine & medical imaging
Severe acute radiation dermatitis after palbociclib therapy in the setting of palliative radiotherapy

Kristine N Kim,Michael Salerno,Payal D Shah,Jennifer Matro,Michael J LaRiviere

DOI: https://doi.org/10.1177/10781552221118841

2022-08-06

Journal of Oncology Pharmacy Practice

Abstract:Journal of Oncology Pharmacy Practice, Ahead of Print. IntroductionCyclin-dependent-kinase 4/6(CDK4/6) inhibitors are widely used as a first-line systemic treatment for patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer. Although many patients with metastatic breast cancer require palliative radiotherapy (RT), there are limited data on the safety of combining a CDK4/6 inhibitor with palliative RT.Case ReportPresented is a case of acute high-grade radiation dermatitis with low-dose palliative RT following administration of palbociclib. A 49-year-old woman with newly diagnosed hormone receptor-positive invasive ductal carcinoma of the left breast presented with lytic bone lesions in the left femur and lumbar spine. The patient initiated treatment with goserelin, tamoxifen, and palbociclib. She underwent prophylactic surgical fixation of the left femur and received post-operative RT encompassing the entire surgical nail (30 Gy/10 fractions) and palliative RT to the lumbar spine for pain relief (20 Gy/5 fractions). During cycle 4, palbociclib was stopped 3 days prior to the start of RT to reduce the risk of toxicity risk. However, 16 days after starting RT, she developed painful erythematous papules and bullae with moist desquamation on the left groin and lumbar spine.Management & OutcomeHer symptoms were managed with topical Aquaphor-lidocaine, silver sulfadiazine, and aluminum acetate soaks. Dermatitis subsided to dry desquamation within 2 weeks. The patient denied late toxicity at 11 months follow-up.DiscussionLarger retrospective or prospective studies are needed to further elucidate the safety of combined CDK4/6 inhibitors and RT. In the meantime, special precautions are warranted in patients receiving combined therapy.

oncology,pharmacology & pharmacy
Radiation recall dermatitis in HER 2 positive breast cancer patients triggered by trastuzumab: A rare case report and review of literature

Jannatul Ferdause,Md Ariful Islam,Nusrat Ahmed,A K M Shafiul Kadir,Md Ariful Haque

DOI: https://doi.org/10.1016/j.ijscr.2024.109864

Abstract:Introduction and importance: Radiation recall dermatitis (RRD) is a localized drug-induced inflammatory skin reaction occurring exclusively in a previously irradiated site months to years after discontinuation of ionizing radiation. The symptoms of RRD can range from mild redness to extensive dermatitis. Antineoplastic drugs such as doxorubicin, docetaxel, paclitaxel, and gemcitabine are most commonly associated with radiation recall reactions. These reactions can also occur with antibiotics and anti-tubercular drugs. Case presentation: A 38-years-old woman with hormone receptor-negative, HER2-positive inflammatory breast cancer (right), clinical stage cT4dN1Mx, received neoadjuvant chemotherapy with AC > TH protocol at 3 weeks intervals (Anthracycline-Doxorubicin plus Cyclophosphamide X 4 cycles, then docetaxel plus Trastuzumab X 4 cycles) followed by modified radical mastectomy followed by adjuvant locoregional radiotherapy. She received the 5th cycle and 6th cycle trastuzumab monotherapy just before the start of surgery and radiotherapy, respectively. After 1 month of completion of radiotherapy, during her seventh cycle of Trastuzumab monotherapy, she developed mild edema with erythematous change over the previously irradiated area with fever. A skin biopsy was taken to exclude any recurrence; however, no evidence of malignancy was found. Clinical discussion: We diagnosed it as a case of RRD. We managed her conservatively. Later, she was rechallenged with the same dose in subsequent cycles with systemic steroid coverage, which she tolerated very well, except for the reappearance of mild erythema following each cycle of maintenance dose of Trastuzumab. Conclusion: Radiation recall dermatitis is an extremely rare phenomenon; hence, an acquaintance of clinicians with this rare entity is essential for timely diagnosis and appropriate management.
Case Report: The many faces of bullous pemphigoid

Laura Rechtien,Lukas Sollfrank,Yannick Foerster,Carola Berking,Michael Sticherling

DOI: https://doi.org/10.3389/fimmu.2023.1272742

2023-10-12

Abstract:The pemphigoid group comprises a number of bullous skin diseases with autoantibodies against different constituents of the basement membrane zone that result in subepidermal detachment and clinically characteristic tense blisters, erosions, urticarial erythema, and itching. Apart from the most frequent type of bullous pemphigoid with antibodies against BP180, which is found predominantly in elderly patients, the disease may present at other ages and different pathogenic conditions. Here, four cases are presented of young age (3 months and 25, 34, and 46 years) and in association with vaccination, pregnancy, or metastatic cancer. Though anti-BP180 was found in all cases, a different pathogenic background may be found in any of them, resulting in characteristic clinical manifestation, yet demanding specifically adapted therapeutic approaches.
Radiation-Induced Laryngeal Mucous Membrane Pemphigoid

Amit Syal,David G Lott,William E Karle

DOI: https://doi.org/10.1177/00034894221139121

Abstract:Objectives: Bullous pemphigoid has previously been linked to radiotherapy, but here we report the first case of MMP suspected to be a consequence of RT. Methods: The patient described is an 85-year-old male who underwent RT to treat squamous cell carcinoma of the palatine tonsil. Shortly after therapy, the patient developed blisters with worsening dyspnea and dysphonia. Results: This patient was successfully treated with a combination of oral immunosuppressants and surgical intervention. Conclusion: This incident underscores that not all episodes of mucosal ulceration following radiation are a result of mucositis and MMP should be considered in the differential. Level of evidence: Level 4.
A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy

Shasha Guan,Linlin Zhang,Junyan Zhang,Wenjing Song,Diansheng Zhong

DOI: https://doi.org/10.3389/fimmu.2022.1068978

IF: 7.3

2023-01-05

Frontiers in Immunology

Abstract:The widespread use of immune checkpoint inhibitors in several malignancies has revealed new immune-related adverse events. Bullous pemphigoid (BP) is an antibody-driven autoimmune disease characterized by skin inflammation and fluid-filled bullae. Herein, a 69-year-old man with lung squamous cell carcinoma developed multiple vesicles and tense bullae 3 weeks after the initiation of a programmed death-1 (PD-1) inhibitor, pembrolizumab, and chemotherapy. Biopsy revealed a subepidermal bulla with lymphocytic and eosinophil infiltration, and immunohistochemical studies predominantly showed CD4 + cells, a few CD8 + cells, and the occasional CD20 + lymphocyte. The serum anti-BP180 antibody level, as well as the interleukin-6 and interleukin-10 levels, were elevated compared to the lower levels of tumor necrosis factor-α. Eosinophil levels were high and consistent with the development of blisters. A diagnosis of BP associated with PD-1 inhibitor therapy was made, and the Common Terminology Criteria for Adverse Events classification was grade 3. Immunotherapy was permanently discontinued, and the patient's bullous lesions failed to react to high-dose systemic corticosteroids combined with minocycline and niacinamide. Intermittent blister recurrence occurred in 2 months, eventually improving with the administration of two courses of intravenous immunoglobulin. At 5 weeks of follow-up, the patient's tumor was reduced on a computed tomographic scan. Despite stable BP treatment, however, he repeatedly developed complications due to the complexity of his underlying disease and could not be treated with anti-tumor therapy. Early recognition and management of serious immune-related bullous dermatologic toxicity are essential for patient safety.

immunology
KRAS mutation in biliary tract cholangiocarcinoma.

S. Yasri,V. Wiwanitkit

DOI: https://doi.org/10.1016/j.jfma.2016.11.008

2017-03-01

Journal of the Formosan Medical Association = Taiwan yi zhi

Abstract:
Roughness-enhanced reliability of MOS tunneling diodes

C. Lin,F. Yuan,C. Shie,K. Chen,B. Hsu,M. Lee,W. Pai,C. Liu

DOI: https://doi.org/10.1109/LED.2002.1015232

IF: 4.8157

2002-08-07

IEEE Electron Device Letters

Abstract:Both electrical and optical reliabilities of PMOS and NMOS tunneling diodes are enhanced by oxide roughness, prepared by very high vacuum prebake technology. For rough PMOS devices, as compared to flat PMOS devices, the Weibull plot of T/sub BD/ shows a 2.5-fold enhancement at 63% failure rate, while both the D/sub 2/ and H/sub 2/-treated flat PMOS devices show similar inferior reliability. For rough NMOS devices, as compared to flat NMOS devices, the Weibull plot of T/sub BD/ shows a 4.9-fold enhancement at 63% failure rate. The time evolutions of the light emission from rough PMOS and NMOS diodes degrade much less than those of flat PMOS and NMOS diodes. The momentum reduction perpendicular to the Si/SiO/sub 2/ interface by roughness scattering could possibly make it difficult to form defects in the bulk oxide and at the Si/SiO/sub 2/ interface by the impact of the energetic electrons and holes.
Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature

Michael Sandhu,Prashanth Ashok Kumar,Jared Deck,Maroun Bou Zerdan,Michael Lacombe,Abirami Sivapiragasam

DOI: https://doi.org/10.1177/23247096231168114

Abstract:Radiation recall dermatitis is an inflammatory reaction of the skin that may infrequently occur in areas of the skin that have been previously treated with radiation therapy. This is thought to be due to a triggering agent administered after radiation therapy which leads to an acute inflammatory reaction, manifesting as a skin rash. We present the case of a 58-year-old male with recurrent invasive squamous cell carcinoma of the tongue, previously treated with chemotherapy and radiation therapy, who presented with progression of his disease. He was treated with pembrolizumab and subsequently developed a new-onset facial rash over the previously treated radiation field. The distribution of the rash was suggestive of radiation recall dermatitis. A biopsy showed dermal necrosis without evidence of dermatitis, vasculitis, or infectious process. This case highlights the incidence of a rare complication of immune checkpoint inhibitor therapy and emphasizes the need for careful monitoring for radiation recall dermatitis.
Neuroendocrine regulation of the stress response in adult zebrafish, Danio rerio

M. Pavlidis,Antonia Theodoridi,A. Tsalafouta

DOI: https://doi.org/10.1016/j.pnpbp.2015.02.014

IF: 5.201

2015-07-03

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Abstract:

Demographics add urgency for action on dementia long-term care.

Delayed and localized pemphigus vulgaris after breast cancer radiotherapy

Post-Irradiation Morphea of the Breast in a Patient with Subacute Cutaneous Lupus Erythematosus: Case Report and a Literature Review

Deformities of the metacarpus and metatarsus in fallow deer (Dama dama L.).

Case report of a delayed diagnosis of radiation induced ulcer in a patient following angioplasty

Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report

[Trichinelliasis, a parasitosis of renewed current interest].

Radiation-induced cutaneous vasculopathy of the breast: a rare case report

Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature

Atypical Presentation of Severe Bullous Pemphigoid: A Case Report

Viral respiratory disease in the intensive care unit.

Ulcerating skin lesions from blastic plasmacytoid dendritic cell neoplasm responding to low-dose radiotherapy—a case report and literature review

Severe acute radiation dermatitis after palbociclib therapy in the setting of palliative radiotherapy

Radiation recall dermatitis in HER 2 positive breast cancer patients triggered by trastuzumab: A rare case report and review of literature

Case Report: The many faces of bullous pemphigoid

Radiation-Induced Laryngeal Mucous Membrane Pemphigoid

A case report of steroid-refractory bullous pemphigoid induced by immune checkpoint inhibitor therapy

KRAS mutation in biliary tract cholangiocarcinoma.

Roughness-enhanced reliability of MOS tunneling diodes

Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature

Neuroendocrine regulation of the stress response in adult zebrafish, Danio rerio